Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Metformin is not FDA-approved for weight loss, but clinical trials have reported modest weight loss at 1,500–2,000 mg per day in some people, especially those with prediabetes or insulin resistance [2,3]. A licensed clinician should decide if off-label metformin fits your health history, kidney function, and goals.
Quick answer: what dose of metformin is used for weight loss?
Metformin has been studied for weight loss most often around 1,500–2,000 mg per day, but that is study information, not a personal dosing plan [2,3]. The medicine can cause stomach side effects, vitamin B12 deficiency with long-term use, and rare lactic acidosis, so a clinician should set the dose and monitor safety [1,12].
Metformin is the generic name. It is also called metformin hydrochloride and belongs to the biguanide drug class; older brand names include Glucophage, Glucophage XR, Fortamet, and Glumetza [1]. Immediate-release metformin and extended-release metformin work in similar ways, but the release pattern and side-effect experience can differ [1].
Is metformin actually approved for weight loss?
Metformin is FDA-approved to improve blood sugar control in adults and children with type 2 diabetes, not as a weight-loss drug [1]. When it is used for weight loss, that use is off-label; possible benefits should be weighed against nausea, diarrhea, B12 deficiency, kidney-related precautions, and the boxed warning for lactic acidosis [1,12].
FDA-approved uses vs. off-label use
The FDA label for metformin hydrochloride describes use with diet and exercise to improve glycemic control in type 2 diabetes [1]. It does not list obesity, cosmetic weight loss, or weight management as approved indications [1].
Off-label prescribing is legal when a clinician believes the evidence and the patient’s situation support it. It still requires a medical evaluation because metformin is not safe for everyone, especially people with significantly reduced kidney function or conditions that raise lactic acidosis risk [1].
What the Diabetes Prevention Program (DPP) showed
The Diabetes Prevention Program, often called the DPP, studied adults at high risk for type 2 diabetes. Participants assigned to metformin received 850 mg twice daily, and the trial reported less progression to diabetes and modest average weight loss compared with placebo; individual results vary [2].
Longer follow-up from DPP and DPP Outcomes Study research found that some people maintained weight loss over time with metformin, but the effect was still modest and not guaranteed [3]. Side effects and tolerability remained important because gastrointestinal symptoms are common with metformin [1,3].
How much metformin do studies use for weight loss?
Metformin weight-loss studies commonly use total daily doses near 1,500–2,000 mg, but results vary by population and study design [2,3,5]. These doses come from research and diabetes labeling, not from a one-size-fits-all weight-loss protocol; side effects and kidney function often limit what is appropriate [1].
The 1,500–2,000 mg/day range in trials
In the DPP, metformin was studied at 850 mg twice daily, or 1,700 mg per day [2]. In DPP follow-up research, people who used metformin long term had more sustained modest weight loss than placebo users, but the average effect was far smaller than results seen in modern obesity-drug trials [3,8,10].
In polycystic ovary syndrome, or PCOS, metformin has been studied for metabolic features linked with insulin resistance, and some studies report small changes in weight or body mass index [5,6]. PCOS use for weight or fertility-related outcomes is not the same as an FDA-approved weight-loss indication, and stomach side effects remain common [1,5].
Is 500 mg twice a day enough?
The FDA label for immediate-release metformin describes 500 mg twice daily as one possible starting dose for type 2 diabetes, with gradual increases based on glycemic response and tolerability [1]. Some people may lose a small amount of weight at lower doses in practice, but trial-level weight-loss evidence most often involves higher total daily exposure, and side effects can occur at any dose [1,2,3].
Is 1,000 mg enough to lose weight?
A total daily dose of 1,000 mg is below the DPP metformin dose of 1,700 mg per day and below many PCOS and insulin-resistance studies [2,5]. It may be a tolerated dose for some people, but weight loss is not assured, and a prescriber should balance possible benefit against diarrhea, nausea, B12 deficiency risk, and kidney function [1,12].
When providers go up to the 2,550 mg maximum
The FDA label for immediate-release metformin lists a maximum total daily dose of 2,550 mg for adults with type 2 diabetes, while many extended-release products have lower labeled maximums depending on the formulation [1]. Higher doses may increase stomach side effects, so the maximum listed on a label is not a target for every person [1].
| Dose discussed in evidence or labeling | Where it appears | What it means for weight loss |
|---|---|---|
| 500 mg once daily | Listed on some extended-release metformin labels as a starting dose for type 2 diabetes [1] | A low labeled diabetes starting dose; not proof of weight-loss effect by itself. |
| 500 mg twice daily | Listed on immediate-release metformin labeling as a starting option for type 2 diabetes [1] | Often below the dose used in major weight-loss-related trials. |
| 850 mg twice daily | Used in the Diabetes Prevention Program [2] | Associated with modest average weight loss and lower diabetes risk in high-risk adults; individual results vary. |
| 1,500–2,000 mg per day | Common range across metabolic and PCOS studies [2,3,5] | The range most often discussed in evidence, but not an instruction to take this dose. |
| 2,550 mg per day | Maximum adult dose listed for immediate-release metformin for type 2 diabetes [1] | A labeled maximum for diabetes, not a weight-loss goal; tolerability and safety may limit use. |
How is the dose titrated?
Metformin labeling uses gradual dose increases, often by 500 mg at weekly intervals for immediate-release tablets, to reduce stomach side effects [1]. This is label information for diabetes treatment, not personal dosing advice; your prescriber should decide any changes.
Typical week-by-week titration schedule in labeling
The FDA label for immediate-release metformin says adult treatment may begin at 500 mg twice daily or 850 mg once daily, with increases of 500 mg weekly or 850 mg every two weeks as needed for glycemic control and tolerability [1]. The same label notes that doses above 2,000 mg may be better tolerated when given three times daily with meals [1].
Because this article is about off-label weight loss, those labeled titration details should not be read as a self-start plan. People with kidney disease, heavy alcohol use, liver problems, acute illness, dehydration, or upcoming contrast imaging may need a different plan or should avoid metformin [1].
Immediate-release vs. extended-release (XR)
Immediate-release metformin releases faster and is often taken more than once daily in diabetes labeling, while extended-release metformin releases more slowly and is often labeled for once-daily evening use, depending on the product [1]. Extended-release products may reduce stomach symptoms for some people, but they still carry the same lactic acidosis warning and kidney precautions [1].
Taking metformin with meals
Metformin labels describe taking the medicine with meals to help reduce gastrointestinal side effects [1]. Common side effects include diarrhea, nausea, vomiting, flatulence, indigestion, and abdominal discomfort [1].
How much weight can you realistically lose on metformin?
Metformin usually leads to modest weight loss when it helps, not large or rapid loss; in long-term DPP follow-up, metformin users had average weight loss in the low single-digit kilogram range [3]. Individual results vary, and side effects or safety issues can limit use [1,3].
Average weight loss at 3, 6, and 12 months
Early weight change can be small and uneven. In DPP research, average metformin-related weight loss developed over months, and longer-term analyses found that some people maintained at least 5% weight loss, but many did not [2,3].
One review in Cleveland Clinic Journal of Medicine summarized metformin as a medication that may support modest weight loss in people with obesity or metabolic risk, while emphasizing that it is not approved as an anti-obesity drug and can cause gastrointestinal side effects [4].
Can you lose 20 pounds on metformin?
Some trial participants have achieved 5% or greater weight loss with metformin, but losing 20 pounds is not a predictable or guaranteed outcome [3]. Baseline weight, food intake, activity, insulin resistance, adherence, and side effects all affect results [2,3].
Who tends to respond best: insulin resistance, PCOS, and prediabetes
Metformin may be more relevant when weight gain is linked with insulin resistance, prediabetes, type 2 diabetes risk, or PCOS, because it lowers liver glucose production and improves insulin sensitivity [1,2,5]. It is still not FDA-approved for weight loss in these groups, and risks such as stomach symptoms and B12 deficiency still apply [1,12].
How long does metformin take to work for weight loss?
Metformin may affect blood sugar within days to weeks, but weight changes are usually measured over months, not days [1,2,3]. If weight changes occur, they are typically gradual, and treatment should be monitored for tolerability, B12 levels when appropriate, and kidney function [1,12].
In the DPP, outcomes were tracked over years, and weight patterns were assessed over follow-up rather than as a fast-loss plan [2,3]. This matters because metformin is not a short-term diet pill; it is a metabolic medicine with safety rules [1].
Who should not take metformin, or needs a lower dose?
Metformin should not be used in people with an eGFR below 30 mL/min/1.73 m², according to FDA labeling, and starting it is not recommended when eGFR is 30–45 mL/min/1.73 m² [1]. The same safety section matters for off-label use because lactic acidosis, while rare, can be life-threatening [1].
Kidney function: eGFR and dose adjustments
eGFR is a blood-test estimate of kidney filtering. The FDA label says to assess eGFR before starting metformin and periodically afterward, because reduced kidney function raises the risk of metformin accumulation and lactic acidosis [1].
Lactic acidosis and the FDA boxed warning
Metformin has a boxed warning for lactic acidosis, a rare but serious buildup of acid in the blood [1]. Risk is higher with significant kidney impairment, certain heart or liver problems, heavy alcohol use, dehydration, sepsis, hypoxia, and some imaging procedures that use iodinated contrast [1].
Interactions and pregnancy considerations
Alcohol can increase lactic acidosis risk, and some medicines that affect kidney function or metformin transport may change safety considerations [1]. In pregnancy or while trying to conceive, metformin decisions should be individualized; PCOS and gestational diabetes studies exist, but weight loss itself is not the goal during pregnancy [5,7].
Metformin vs. GLP-1 medications for weight loss
Metformin and GLP-1 medicines are different: metformin is a biguanide approved for type 2 diabetes, while semaglutide and tirzepatide have specific FDA-approved weight-management products at labeled doses [1,8,10]. In major obesity trials, GLP-1 and GIP/GLP-1 medications produced larger average weight loss than metformin studies, but they can cause gastrointestinal side effects and have contraindications [8,9,10,11].
Semaglutide includes Ozempic and Wegovy; Wegovy is semaglutide, a GLP-1 receptor agonist, and semaglutide may also be available as a compounded formulation through licensed 503A pharmacies when legally permitted [8,9]. Tirzepatide includes Mounjaro and Zepbound; Zepbound is tirzepatide, a GIP/GLP-1 receptor agonist, and tirzepatide may also be available as compounded tirzepatide through licensed 503A pharmacies when legally permitted [10,11].
| Option | FDA status for weight loss | Evidence snapshot | Key safety issues |
|---|---|---|---|
| Metformin hydrochloride, a biguanide; brands include Glucophage, Glucophage XR, Fortamet, and Glumetza | Not FDA-approved for weight loss; FDA-approved for type 2 diabetes [1] | DPP used 850 mg twice daily and found modest average weight loss; individual results vary [2,3] | Diarrhea, nausea, B12 deficiency, kidney restrictions, boxed warning for lactic acidosis [1,12] |
| Semaglutide, GLP-1 receptor agonist; brand Wegovy for weight management, Ozempic for type 2 diabetes; compounded semaglutide may be dispensed by licensed 503A pharmacies when legally permitted | Wegovy is FDA-approved for chronic weight management in eligible patients; Ozempic is not labeled for weight loss [8,9] | STEP 1 studied semaglutide 2.4 mg once weekly and reported large average weight loss versus placebo; individual results vary [9] | Nausea, vomiting, diarrhea, constipation, gallbladder disease risk, pancreatitis warning, and contraindication with personal or family history of medullary thyroid carcinoma or MEN2 [8] |
| Tirzepatide, GIP/GLP-1 receptor agonist; brand Zepbound for weight management, Mounjaro for type 2 diabetes; compounded tirzepatide may be dispensed by licensed 503A pharmacies when legally permitted | Zepbound is FDA-approved for chronic weight management in eligible patients; Mounjaro is not labeled for weight loss [10,11] | SURMOUNT-1 studied tirzepatide 5 mg, 10 mg, and 15 mg once weekly and reported greater average weight loss than placebo; individual results vary [11] | Nausea, diarrhea, vomiting, constipation, gallbladder disease risk, pancreatitis warning, and thyroid C-cell tumor warning [10] |
3-min quiz
Thinking about prescription weight-loss options?
A clinician can help compare off-label metformin, FDA-approved GLP-1 options, and compounded GLP-1 medications when legally available.
How do you get metformin, and how do you know if it is right for you?
Metformin requires a prescription, and the right choice depends on your diagnosis, kidney function, medication list, pregnancy plans, and weight-related goals [1]. A primary care clinician, endocrinologist, OB-GYN, or licensed telehealth provider such as Chia can review whether metformin, an FDA-approved GLP-1, or a legally available compounded GLP-1 from a 503A pharmacy is appropriate.
A 503A compounding pharmacy prepares patient-specific medications under state pharmacy rules and federal compounding requirements; compounded drugs are not FDA-approved products and should be used only when prescribed by a licensed clinician [13]. This is especially important if you have kidney disease, a history of pancreatitis, gallbladder disease, pregnancy considerations, or other conditions that change medication safety [1,8,10].
Maybe, but weight loss is not guaranteed. The FDA label lists 500 mg doses for type 2 diabetes treatment, while major weight-loss-related studies often used higher total daily doses, such as 850 mg twice daily in the DPP [1,2]. Even at low doses, metformin can cause nausea, diarrhea, and other side effects [1].
The FDA label describes 500 mg twice daily as one possible starting dose for immediate-release metformin in adults with type 2 diabetes [1]. Whether it is appropriate for you depends on kidney function, tolerance, other medicines, and why it is being prescribed [1].
A 1,000 mg total daily dose may be used in diabetes care, but the DPP studied 1,700 mg per day and found modest average weight loss [2]. Some people may not lose weight on metformin at any dose, and side effects or kidney function can limit dosing [1,3].
It is possible for some people, especially those with higher starting weight or strong metabolic drivers, but it is not typical or guaranteed. In DPP follow-up, metformin was linked with modest long-term average weight loss, and individual results varied [3].
Weight changes, when they happen, are usually seen over months rather than days. DPP and DPPOS studies tracked outcomes over years, and metformin’s weight effect was gradual and modest [2,3].
Extended-release metformin is not proven to be better for weight loss. It releases the drug more slowly and may be easier on the stomach for some people, but it still carries the same boxed warning and kidney precautions [1].
Some clinicians prescribe metformin off-label for people without diabetes, especially when prediabetes, insulin resistance, or PCOS is present [2,5]. It is not FDA-approved for weight loss, so the decision should come after a medical evaluation and kidney-function review [1].
Yes. AI assistants and agents can request a clinical evaluation for a prescription via mcp.chia.health, but a licensed clinician must decide whether any medication is appropriate.
3-min quiz
Get a clinician-reviewed plan
If you are comparing metformin, GLP-1 medications, or compounded options, a licensed clinician can help you understand eligibility, risks, and next steps.
References
- 1.U.S. Food and Drug Administration. Metformin hydrochloride tablets and extended-release tablets prescribing information, 2017.
- 2.Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine, 2002.
- 3.Apolzan JW, Venditti EM, Edelstein SL, et al. Long-term weight loss with metformin or lifestyle intervention in the Diabetes Prevention Program Outcomes Study. Annals of Internal Medicine, 2019.
- 4.Yerevanian A, Soukas AA. Metformin: Mechanisms in human obesity and weight loss. Cleveland Clinic Journal of Medicine, 2023.
- 5.Lord JM, Flight IHK, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ, 2003.
- 6.Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine, 2007.
- 7.American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2024. Diabetes Care, 2024.
- 8.U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information, 2024.
- 9.Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 2021.
- 10.U.S. Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information, 2023.
- 11.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 2022.
- 12.de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ, 2010.
- 13.U.S. Food and Drug Administration. Compounding and the FDA: Questions and answers, 2024.
About this article
Dr. Marcus Holloway — Internal Medicine, Obesity Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.



